Knobbe Martens advises Paragonix Technologies on the definitive agreement to acquire Getinge

Paragonix Technologies, a leading organ transplant company, recently announced that it has entered into a definitive agreement to acquire Getinge.

This strategic acquisition will expand Getinge’s global healthcare portfolio while also addressing the need for solid organ transplantation.

Getinge’s global presence will expand Paragonix’s innovative organ transplant technologies into new markets, as well as create opportunities to combine the two companies’ organ containment and blood perfusion technologies to create new innovations. Paragonix and Getinge share a vision of providing market-leading solutions across the entire spectrum of graft care.

Nobbe Martens’ team advising Paragonix included Subing Lee, co-chair of the company’s medical devices and procedures practice, David Schmidt, Ph.D., Catherine Holland and James Raleigh.

“Every day we are inspired to bring new, life-changing innovations to the transplant and donor communities. We extend our deepest gratitude to the clinical and donor community for the opportunity to serve.”

Paragonix has led the development of a platform of revolutionary organ preservation technologies, driving shifts in the clinical transplant community and redefining the standard of care in organ transplantation. Today, Paragonix is ​​the leading provider of cardiothoracic organ preservation technologies in the United States and is rapidly expanding its use in abdominal transplantation.

Paragonix has developed a broad portfolio of solutions to meet the needs of the transplant community, including leading clinical research initiatives, smart digital logistics platforms and national clinical service networks. By combining leadership in transplantation with Getinge’s extensive resources and global distribution network, this acquisition will accelerate the availability of this revolutionary medical technology. The agreement will also promote the creation of new technologies that meet critical global health needs.

The boards of directors of Paragonix and Getinge have approved the transaction pending the satisfaction of customary closing conditions. Upon closing, Paragonix will become a subsidiary of Getinge.

Sheppard, Mullin, Richter & Hampton LLP served as legal counsel, Knobbe Martens Olson & Bear served as intellectual property counsel, and UBS Investment Bank Securities served as exclusive financial advisor to Paragonix.

Knobbe Martens serves a diverse international client base, from multinational corporations to start-ups at all stages.